Meglumine Market Size, Share, Growth, and Global Industry Analysis, By Type (Diatrizoate, Iothalamate, Iodipamide), By Application (Cosolvent, Contrast agent and Others), Regional Outlook, and Forecast From 2026 to 2035

• 

  Download Free Sample to learn more about this report

MEGLUMINE MARKET OVERVIEW

The global Meglumine Market is estimated to be valued at approximately USD 0.01 Billion in 2026. The market is projected to reach USD 0.02 Billion by 2035, expanding at a CAGR of 7.8% from 2026 to 2035.

Meglumine is a white crystalline powder with the molecular formula C₇H₁₇NO₅. Its molecular mass is 195.214 gmol^-. It is soluble in water, slightly soluble in ethanol, almost insoluble in chloroform. It has a melting point between 128℃ to 132℃. The boiling point is 490.4ºC at 760 mmHg. Its density is 1.375gcm^3- and has a taste of sweet and salty astringent. It can be stored in powder form at -20°C for 3 years and at 4°C for 2 years. In solvent form it can be stored at -80°C for 6 months and -20°C for a month.

It is an amino sugar derived from sorbitol. It is also known as methylglucamine. It is an organic compound and belongs to hexosamines. They are monosaccharides which have a sugar unit consisting of six-carbons. It is a weak acid. It is widely known in pharmaceuticals by its types. It is also a radiopaque compound used in studying x-rays. The different uses of this compound facilitates the growth of the global meglumine market.

COVID-19 Impact

Travel Bans Hampered Market Growth

The global COVID-19 pandemic has been unprecedented and staggering, with it experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The spike in CAGR is attributable to the meglumine market growth and demand returning to pre-pandemic levels once the pandemic is over.

Globally, the COVID-19 pandemic's consequences are already being seen, and this has had a big impact on the market. The COVID-19 outbreak had a detrimental effect on a number of markets. Lockdowns were implemented in several nations. All types of enterprises and chemical plants experienced disruptions as a result of the rapid outbreak. Various industries were affected by the pandemic's restrictions, and this was one among them. A halt in production operations had an impact on meglumine demand. Pharmaceuticals were greatly impacted by the pandemic, which led to the establishment of work-from-home policies. Complete lockdown was required due to the infection's propagation, which had a detrimental effect on consumer demand and market expansion.

LATEST TRENDS

Capability of Diagnosing Different Diseases to Improve Market Growth

As a diagnostic drug for gastrointestinal radiography, it can be used for the diagnosis of vascular diseases, biliary tract disorders, renal and urinary tract disorders, and disc and joint disorders. It is also used as a contrast agent in the diagnosis of joint and disc diseases, contrast enhancers in computed tomography of the body, gastrointestinal disorders and heart diseases. It is absorbed in small amounts through the gastrointestinal tract. Its binding to plasma proteins is low and if the kidney is functioning normally, its plasma half-life is 30-60 minutes. These uses urge the pharmaceuticals to increase production rate. Such demands are expected to pose an opportunity for the meglumine market growth during the forecast period.

• According to the World Health Organization, noncommunicable diseases account for 41 million deaths annually, representing nearly 74% of global deaths, leading to increased diagnostic imaging procedures where meglumine salts are used in contrast media formulations. Additionally, according to the Organisation for Economic Co-operation and Development, OECD countries perform more than 150 CT scans per 1,000 population annually in advanced healthcare systems, supporting demand for iodinated contrast agents containing meglumine.

• According to the International Pharmaceutical Federation, over 3 million pharmacists are practicing worldwide, contributing to expanding pharmaceutical production and formulation activities where meglumine is used as a solubilizing agent. Furthermore, according to the United Nations Industrial Development Organization, the global pharmaceutical manufacturing sector operates across more than 150 countries, increasing excipient demand including amino sugar derivatives like meglumine.

Download Free Sample to learn more about this report

MEGLUMINE MARKET SEGMENTATION

By Type

Based on type; the market is divided into diatrizoate, Iothalamate, Iodipamide. Diatrizoate is the leading part in the type segment.

• Diatrizoate Meglumine: Diatrizoate Meglumine commands approximately 48% of Meglumine Market Share, supported by its widespread use in over 30 million X-ray and CT contrast procedures annually. The compound exhibits iodine content levels around 370 mg iodine per mL in injectable formulations, ensuring radiopacity efficiency exceeding 95% diagnostic clarity rates. North America accounts for nearly 36% of Diatrizoate Meglumine demand, driven by more than 80 million CT scans conducted per year. Manufacturing facilities produce batches exceeding 5,000 kg per production cycle, maintaining impurity thresholds below 0.5%. The Meglumine Market Insights confirm consistent pharmaceutical utilization across more than 120 regulated countries, strengthening Meglumine Market Growth and Meglumine Industry Analysis.

• Lothalamate Meglumine: Lothalamate Meglumine represents approximately 32% of Meglumine Market Size, primarily utilized in intravenous urography procedures exceeding 12 million cases annually. Formulations commonly contain iodine concentrations of 282 mg to 400 mg per mL, ensuring high imaging precision. Europe contributes nearly 29% of Lothalamate Meglumine consumption, supported by over 15,000 diagnostic imaging centers. Stability profiles demonstrate shelf life periods up to 36 months under controlled storage below 25°C. Pharmaceutical production volumes exceed 3,500 kg annually per major manufacturing site, ensuring consistent supply. The Meglumine Market Forecast highlights regulatory compliance across more than 90 pharmacopoeia standards, reinforcing Meglumine Market Opportunities in diagnostic imaging.

• Lodipamide Meglumine: Lodipamide Meglumine accounts for approximately 20% of Meglumine Market Share, with application in cholecystographic imaging procedures exceeding 5 million annually worldwide. Iodine concentration levels range between 300 mg and 350 mg per mL, delivering radiographic visibility rates above 90% in biliary diagnostics. Asia-Pacific holds nearly 41% of Lodipamide Meglumine demand, reflecting expanding diagnostic infrastructure exceeding 25,000 hospitals. Batch production purity exceeds 98.5%, with moisture content maintained below 1.0%. The Meglumine Market Analysis indicates packaging in volumes from 10 mL to 100 mL vials, supporting Meglumine Market Growth and Meglumine Industry Report performance benchmarks across specialized imaging centers.

By Application

Based on application; the market is divided into cosolvent, contrast agent and the others. Cosolvent is the leading part in the application segment.

• Cosolvent: Cosolvent applications account for approximately 23% of Meglumine Market Share, with usage in over 8 million pharmaceutical formulations annually. Meglumine acts as a stabilizing agent in injectables and oral solutions, improving solubility rates by 15% to 25% for poorly soluble APIs. Pharmaceutical manufacturing facilities exceeding 20,000 globally integrate meglumine salts into production lines. North America and Europe together contribute nearly 58% of cosolvent demand, supported by advanced drug formulation labs numbering over 12,000 units. The Meglumine Market Research Report highlights pH stabilization ranges between 6.5 and 7.5, enhancing formulation compatibility, strengthening Meglumine Market Outlook and Meglumine Market Trends in B2B pharmaceutical supply chains.

• Contrast Agent: Contrast Agent applications dominate with nearly 67% of Meglumine Market Size, driven by over 45 million contrast-enhanced imaging procedures annually. CT scans exceed 80 million cases per year globally, with contrast usage rates above 60% in abdominal and vascular imaging. Diatrizoate and Lothalamate formulations represent more than 70% of iodine-based contrast agents containing meglumine salts. Europe accounts for approximately 28% of contrast agent demand, while North America holds 35%. Dosage volumes range from 50 mL to 150 mL per patient, depending on imaging protocol. The Meglumine Market Analysis confirms consistent utilization across more than 100,000 diagnostic imaging centers, reinforcing Meglumine Market Growth and Meglumine Market Insights.

• Other: Other applications contribute approximately 10% of Meglumine Market Share, including veterinary imaging and specialty pharmaceutical preparations exceeding 3 million annual doses. Veterinary diagnostic centers number over 35,000 worldwide, supporting meglumine-based contrast usage in animal imaging. Specialty formulations demonstrate stability periods exceeding 24 months under controlled storage conditions. Asia-Pacific accounts for nearly 33% of other application demand, driven by expanding veterinary infrastructure exceeding 18% facility growth over 5 years. The Meglumine Market Outlook highlights packaging volumes between 5 mL and 50 mL, supporting Meglumine Market Opportunities and Meglumine Industry Analysis diversification across niche segments.

MARKET DYNAMICS

Market dynamics refer to the combination of drivers, restraints, opportunities, and challenges that influence industry performance, demand patterns, and competitive positioning across regions. These factors collectively determine market expansion, technology adoption rates, regulatory impact, and long-term sustainability of the industry.

Driving Factors

Uses in X-rays to Increase Meglumine Production

The meglumine market share is anticipated to increase with the increase in the uses of this compound particularly in the hospitals. Diatrizoate meglumine is the salt form of diatrizoate, an organic, iodinated, radiopaque X-ray contrast medium used in diagnostic radiography. The iodine moiety of this is non-penetrable by X-rays, therefore blocks the tissues from the X-ray film exposure by radiation. This makes it possible to distinguish on X-ray film, body parts that contain this drug from body parts that do not contain this agent and allows for visualization of different body structures. This drug proved its efficiency in the field of medicine. Such demand from the health sector is anticipated to drive the market.

• According to the World Bank, global health expenditure accounted for approximately 9.8% of global GDP in recent assessments, reflecting sustained growth in medical diagnostics and pharmaceutical demand. Additionally, according to the Ministry of Health and Family Welfare, India operates more than 70,000 public and private hospitals, strengthening the demand for injectable contrast formulations containing meglumine compounds.

• According to the Centers for Disease Control and Prevention, approximately 37 million adults in the United States have chronic kidney disease, increasing imaging requirements that often involve contrast media. Moreover, according to the World Heart Federation, cardiovascular diseases cause nearly 20.5 million deaths annually, supporting high imaging volumes in cardiology diagnostics.

Product’s Ability to Cure Diseases to Lead Market Growth

Visceral leishmaniasis, also known as kala-azar or black fever, is the most severe form of leishmaniasis and, without proper diagnosis and treatment, is associated with high fatality. Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania. This created a huge demand for this compound in the industry. Meglumine antimoniate can be used to treat an infection called leishmaniasis. There are several other diseases also which can be cured with the help of this drug. This helps the pharmaceuticals to produce more of the drug to satisfy its need in the market. Such companies are anticipated to drive the market growth during the forecast period.

Restraining Factor

Side Effects of the Drug to Impede Market Growth

The Iothalamate meglumine cannot be directly applied to the spine. Very bad and sometimes deadly allergic reactions have rarely happened. Serious health problems, paralysis, and death have happened when contrast has been given into blood vessels in the spinal cord.  blood clots can happen with iothalamate type when used with some procedures. Sometimes, blood clots may cause heart attack and stroke, which may be deadly. Thyroid problems can also occur after use of diatrizoate and iodipamide meglumine. Since it is given in the cervix by the doctor, blood in urine and bladder irritation are also its side effects. Any patients with a history of asthma cannot use this drug. These factors restrict the growth of the meglumine market.

• According to the Food and Drug Administration, adverse event reporting systems record thousands of drug-related safety reports annually, including those related to contrast media reactions. Additionally, according to the European Medicines Agency, safety reviews have led to updated usage restrictions and monitoring guidelines across 27 EU member states, influencing meglumine-based contrast utilization.

• According to the United Nations Environment Programme, over 2 million tonnes of pharmaceutical residues enter ecosystems annually through wastewater discharge. Furthermore, according to the World Health Organization, pharmaceutical contamination has been detected in drinking water sources across more than 50 countries, prompting tighter manufacturing and disposal controls.

Rising Diagnostic Imaging Procedures Globally

Opportunity

Global diagnostic imaging volumes exceed 4 billion procedures annually, with CT and X-ray procedures surpassing 200 million cases per year. Aging populations exceeding 770 million individuals aged 65 and above increase chronic disease prevalence by over 20%, driving imaging demand. Emerging economies added more than 10,000 new imaging facilities over 5 years, expanding contrast agent accessibility. Iodine-based contrast media usage exceeds 75% of total contrast-enhanced scans, reinforcing meglumine demand. Hospital infrastructure growth surpasses 15% expansion in developing markets, supporting Meglumine Market Growth, Meglumine Market Opportunities, and Meglumine Market Forecast across pharmaceutical-grade production networks.

• According to the International Atomic Energy Agency, more than 4,000 medical radiotherapy centers operate worldwide, and imaging facilities continue expanding in developing regions. Additionally, according to the World Bank, middle-income countries account for over 75% of the global population, representing substantial potential for growth in diagnostic imaging services that use meglumine-based products.

• According to the World Trade Organization, pharmaceutical products represent over USD 800 billion worth of global exports annually, including generic formulations. In India, according to the Department of Pharmaceuticals, the country hosts more than 3,000 drug manufacturing companies and over 10,500 manufacturing units, supporting demand for pharmaceutical-grade excipients such as meglumine.

Regulatory Compliance and Adverse Reaction Risks

Challenge

Adverse reaction incidence rates for iodine-based contrast agents range between 0.2% and 0.7% per administration, necessitating strict pharmacovigilance across more than 120 regulatory jurisdictions. Manufacturing standards require impurity levels below 0.5% and endotoxin limits under 0.25 EU/mL, increasing quality control costs. Approximately 38% of smaller pharmaceutical manufacturers report compliance challenges with updated good manufacturing practice standards. Storage temperature control between 15°C and 25°C is mandatory to maintain product stability over 24 to 36 months. Annual regulatory audits exceed 1 inspection per facility, impacting Meglumine Market Outlook and Meglumine Industry Report operational scalability.

• According to the United States Pharmacopeia, pharmaceutical excipients must meet defined monograph specifications for purity and impurity limits, often measured in parts per million. Additionally, according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, impurity thresholds for active and inactive ingredients are tightly regulated across major markets, increasing compliance costs.

• According to the Organisation for Economic Co-operation and Development, specialty chemical production is concentrated in fewer than 15 major producing countries, creating vulnerability to disruptions. Furthermore, according to the United Nations Conference on Trade and Development, global chemical trade volumes exceed USD 2 trillion annually, indicating strong cross-border dependency for raw materials used in meglumine production.

• Download Free Sample to learn more about this report

•  

MEGLUMINE MARKET REGIONAL INSIGHTS

Europe to Dominate Market due to its Climatic Conditions

Europe holds the largest part of the meglumine market share due to the largest countries such as Spain, Germany having its leading producers. The demand for the drug is attributed to the ability of it to be used to treat various diseases. These countries also can have the climatic conditions that are suitable for the storage of this drug. New production facilities for this compound also contributed to the growth in the establishment of various manufacturer companies to facilitate the market growth in the region.     

KEY INDUSTRY PLAYERS

Market Players to Expand Market Growth

The report presents data about the rundown of market players and their activities in the business. The data is gathered and announced with appropriate examination, mechanical turns of events, acquisitions, consolidations, growing creation lines, and organizations. Different perspectives analyzed for this market incorporate organizations delivering and presenting new offices, districts they lead their tasks in, robotization, innovation reception, limit, creating the most over the top income, and having an effect with their items.

• Merck: Merck operates in more than 65 countries and employs approximately 60,000+ people, supplying pharmaceutical-grade chemicals and excipients to global markets.

• Tianma: Tianma operates multiple production facilities in China and supplies active pharmaceutical ingredients and intermediates to more than 40 countries, supporting excipient and contrast media markets.

List Of Top Meglumine Companies

•  Merck (New Jersey, U.S.)
• Tianma (Yunnan, China)
• Libang Healthcare Group (Shaanxi, China)
• New Hualian Pharm (Shanghai, China)

REPORT COVERAGE

This examination conveys a report with broad examinations that take into portrayal of the organizations that exist in the market influencing the estimating time frame. Additionally, the report reveals insight into the extensive serious scene of the global market. The report further offers a dashboard outline of driving organizations enveloping their fruitful promoting procedures, extension, market commitment, late improvements in both memorable and present settings. With investigations done, it additionally offers an exhaustive examination by reviewing the variables like division, potential open doors, modern turns of events, patterns, development, size, shares, drivers, restrictions, and others. This examination is dependent upon future developments assuming that the central participants and plausible investigation of market elements changes.